BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li G, De Clercq E. Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Res. 2017;142:83-122. [PMID: 28238877 DOI: 10.1016/j.antiviral.2017.02.014] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 18.6] [Reference Citation Analysis]
Number Citing Articles
1 Okui T, Nakashima N. Analysis of the association between areal socioeconomic deprivation levels and viral hepatitis B and C infections in Japanese municipalities. BMC Public Health 2022;22:681. [PMID: 35392863 DOI: 10.1186/s12889-022-13089-w] [Reference Citation Analysis]
2 da Silva RP, Gonçalves JIB, Zanin RF, Schuch FB, de Souza APD. Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis. Front Immunol 2021;12:657363. [PMID: 34054820 DOI: 10.3389/fimmu.2021.657363] [Reference Citation Analysis]
3 Pedergnana V, Irving WL, Barnes E, McLauchlan J, Spencer CCA. Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients. J Interferon Cytokine Res 2019;39:642-9. [PMID: 31260374 DOI: 10.1089/jir.2019.0013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Troost B, Smit JM. Recent advances in antiviral drug development towards dengue virus. Curr Opin Virol 2020;43:9-21. [PMID: 32795907 DOI: 10.1016/j.coviro.2020.07.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
5 Ding Y, Li G, Zhou Z, Deng T. Molecular mechanisms underlying hepatitis C virus infection-related diabetes. Metabolism 2021;121:154802. [PMID: 34090869 DOI: 10.1016/j.metabol.2021.154802] [Reference Citation Analysis]
6 Alazard-Dany N, Denolly S, Boson B, Cosset FL. Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets. Viruses. 2019;11. [PMID: 30621318 DOI: 10.3390/v11010030] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
7 Gómez ME, Gentile EA, Martini MF, Cuestas ML, Mathet VL, Moltrasio GY, Moglioni AG. Synthesis of New Indanyl Nucleoside Analogues and their Biological Evaluation on Hepatitis C Virus (HCV) Replicon. Molecules 2019;24:E990. [PMID: 30862130 DOI: 10.3390/molecules24050990] [Reference Citation Analysis]
8 Zając M, Muszalska I, Sobczak A, Dadej A, Tomczak S, Jelińska A. Hepatitis C - New drugs and treatment prospects. Eur J Med Chem 2019;165:225-49. [PMID: 30685524 DOI: 10.1016/j.ejmech.2019.01.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
9 Park YJ, Woo HY, Heo J, Park SG, Hong YM, Yoon KT, Kim DU, Kim GH, Kim HH, Song GA, Cho M. Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution. Gut Liver 2021;15:440-50. [PMID: 32839365 DOI: 10.5009/gnl19393] [Reference Citation Analysis]
10 Buggisch P, Heiken H, Mauss S, Weber B, Jung MC, Görne H, Heyne R, Hinrichsen H, Hidde D, König B, Pires Dos Santos AG, Niederau C, Berg T. Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study. PLoS One 2021;16:e0250833. [PMID: 33970940 DOI: 10.1371/journal.pone.0250833] [Reference Citation Analysis]
11 Pecoraro V, Banzi R, Cariani E, Chester J, Villa E, D'Amico R, Bertele' V, Trenti T. New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. J Clin Exp Hepatol 2019;9:522-38. [PMID: 31516269 DOI: 10.1016/j.jceh.2018.07.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
12 Velázquez-Moctezuma R, Augestad EH, Castelli M, Holmboe Olesen C, Clementi N, Clementi M, Mancini N, Prentoe J. Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies. Vaccines (Basel) 2021;9:291. [PMID: 33804732 DOI: 10.3390/vaccines9030291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Sohora M, Vazdar M, Sović I, Mlinarić-Majerski K, Basarić N. Photocyclization of Tetra- and Pentapeptides Containing Adamantylphthalimide and Phenylalanines: Reaction Efficiency and Diastereoselectivity. J Org Chem 2018;83:14905-22. [PMID: 30460849 DOI: 10.1021/acs.joc.8b01785] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
14 Stephens DB, Young AM, Havens JR. Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs. Int J Drug Policy 2017;47:86-94. [PMID: 28648353 DOI: 10.1016/j.drugpo.2017.05.045] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
15 Pérez AB, Chueca N, García-deltoro M, Martínez-sapiña AM, Lara-pérez MM, García-bujalance S, Aldámiz-echevarría T, Vera-méndez FJ, Pineda JA, Casado M, Pascasio JM, Salmerón J, Alados-arboledas JC, Poyato A, Téllez F, Rivero-juárez A, Merino D, Vivancos-gallego MJ, Rosales-zábal JM, García F, Ocete MD, Simón MÁ, Rincón P, Reus S, De la Iglesia A, García-arata I, Jiménez M, Jiménez F, Hernández-quero J, Galera C, Balghata MO, Primo J, Masiá M, Espinosa N, Delgado M, von-Wichmann MÁ, Collado A, Santos J, Mínguez C, Díaz-flores F, Fernández E, Bernal E, De Juan J, Antón JJ, Vélez M, Aguilera A, Navarro D, Arenas JI, Fernández C, Espinosa MD, Ríos MJ, Alonso R, Hidalgo C, Hernández R, Téllez MJ, Rodríguez FJ, Antequera P, Delgado C, Martín P, Crespo J, Becerril B, Pérez Ó, García-herola A, Montero J, Freyre C, Grau C. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. Journal of Hepatology 2019;71:876-88. [DOI: 10.1016/j.jhep.2019.06.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
16 Brown RS, Buti M, Rodrigues L, Chulanov V, Chuang W, Aguilar H, Horváth G, Zuckerman E, Carrion BR, Rodriguez-perez F, Urbánek P, Abergel A, Cohen E, Lovell SS, Schnell G, Lin C, Zha J, Wang S, Trinh R, Mensa FJ, Burroughs M, Felizarta F. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial. Journal of Hepatology 2020;72:441-9. [DOI: 10.1016/j.jhep.2019.10.020] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 23.5] [Reference Citation Analysis]
17 Shanmugam S, Nichols AK, Saravanabalaji D, Welsch C, Yi M. HCV NS5A dimer interface residues regulate HCV replication by controlling its self-interaction, hyperphosphorylation, subcellular localization and interaction with cyclophilin A. PLoS Pathog 2018;14:e1007177. [PMID: 30036383 DOI: 10.1371/journal.ppat.1007177] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
18 Meshram RJ, Kathwate GH, Gacche RN. Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections. Arch Virol 2022. [PMID: 35089390 DOI: 10.1007/s00705-022-05375-0] [Reference Citation Analysis]
19 Meanwell NA, Belema M. The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex. In: Sofia MJ, editor. HCV: The Journey from Discovery to a Cure. Cham: Springer International Publishing; 2019. pp. 27-55. [DOI: 10.1007/7355_2018_47] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
20 Martinez MA. Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment. Front Immunol 2021;12:635371. [PMID: 33777024 DOI: 10.3389/fimmu.2021.635371] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
21 Atty SA, Mohamed MA, Abd el halim LM, Fouad FA, Boukherroub R. Graphite/Nanocrystalline Zeolite Platform for Selective Electrochemical Determination of Hepatitis C Inhibitor Ledipasvir. Electroanalysis 2018;31:1215-23. [DOI: 10.1002/elan.201800500] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
22 Abd El-wahab EW, Ayoub HA, Shorbila AA, Mikheal A, Fadl M, Kotkat AM. Noninvasive biomarkers predict improvement in liver fibrosis after successful generic DAAs based therapy of chronic hepatitis C in Egypt. Clinical Epidemiology and Global Health 2020;8:1177-88. [DOI: 10.1016/j.cegh.2020.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Sorbo MC, Cento V, Di Maio VC, Howe AYM, Garcia F, Perno CF, Ceccherini-Silberstein F. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resist Updat 2018;37:17-39. [PMID: 29525636 DOI: 10.1016/j.drup.2018.01.004] [Cited by in Crossref: 98] [Cited by in F6Publishing: 94] [Article Influence: 24.5] [Reference Citation Analysis]
24 Atta NF, Galal A, Ahmed YM. New strategy for determination of anti-viral drugs based on highly conductive layered composite of MnO2/graphene/ionic liquid crystal/carbon nanotubes. Journal of Electroanalytical Chemistry 2019;838:107-18. [DOI: 10.1016/j.jelechem.2019.02.056] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
25 Patil VM, Singhal S, Masand N. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. Life Sci 2020;254:117775. [PMID: 32418894 DOI: 10.1016/j.lfs.2020.117775] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
26 Li Z, Liu Q. Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A. J Gen Virol. 2018;99:44-61. [PMID: 29235977 DOI: 10.1099/jgv.0.000987] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
27 Crespo J, Lázaro de Mercado P, Blasco Bravo AJ, Aguilera Guirao A, García-samaniego Rey J, Eiros Bouza JM, Luis Calleja Panero J, García F. El diagnóstico de la infección por el virus de la hepatitis C en España: una oportunidad para mejorar. Enfermedades Infecciosas y Microbiología Clínica 2019;37:231-8. [DOI: 10.1016/j.eimc.2018.05.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
28 Crespo J, Lázaro P, Blasco AJ, Aguilera A, García-Samaniego J, Eiros JM, Calleja JL, García F. Hepatitis C reflex testing in Spain in 2019: A story of success. Enferm Infecc Microbiol Clin (Engl Ed) 2021;39:119-26. [PMID: 32451150 DOI: 10.1016/j.eimc.2020.03.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
29 Mesalam AA, Desombere I, Farhoudi A, Van Houtte F, Verhoye L, Ball J, Dubuisson J, Foung SKH, Patel AH, Persson MAA, Leroux-Roels G, Meuleman P. Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1. Virology 2018;514:30-41. [PMID: 29128754 DOI: 10.1016/j.virol.2017.10.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
30 Abdel Karim SE, Youssef YH, Abdel-Halim M, Frakolaki E, Vassilaki N, Zoidis G, Ahmed NS, Abadi AH. Symmetric benzidine derivatives as anti-HCV agents: Insight into the nature, stereochemistry of the capping amino acid and the size of the terminal capping carbamates. Bioorg Chem 2020;102:104089. [PMID: 32717691 DOI: 10.1016/j.bioorg.2020.104089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Kendall CE, Fitzgerald M, Donelle J, Kwong JC, Galanakis C, Boyd R, Cooper CL. A cross-sectional study of prolonged disengagement from clinic among people with HCV receiving care in a low-threshold, multidisciplinary clinic. CanLivJ 2020;3:212-23. [DOI: 10.3138/canlivj.2019-0020] [Reference Citation Analysis]
32 Shiryaev VA, Radchenko EV, Palyulin VA, Zefirov NS, Bormotov NI, Serova OA, Shishkina LN, Baimuratov MR, Bormasheva KM, Gruzd YA, Ivleva EA, Leonova MV, Lukashenko AV, Osipov DV, Osyanin VA, Reznikov AN, Shadrikova VA, Sibiryakova AE, Tkachenko IM, Klimochkin YN. Molecular design, synthesis and biological evaluation of cage compound-based inhibitors of hepatitis C virus p7 ion channels. Eur J Med Chem 2018;158:214-35. [PMID: 30218908 DOI: 10.1016/j.ejmech.2018.08.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
33 Rahman M, Hossain ME, Afrad MH, Hasan R, Rahman M, Sarker MS, Azim T. Hepatitis C virus infections among clients attending an HIV testing and counseling center in Dhaka, Bangladesh. J Med Virol 2018;90:383-7. [PMID: 28960396 DOI: 10.1002/jmv.24955] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
34 Qin Y, Xue B, Liu C, Wang X, Tian R, Xie Q, Guo M, Li G, Yang D, Zhu H. NLRX1 Mediates MAVS Degradation To Attenuate the Hepatitis C Virus-Induced Innate Immune Response through PCBP2. J Virol 2017;91:e01264-17. [PMID: 28956771 DOI: 10.1128/JVI.01264-17] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 7.4] [Reference Citation Analysis]
35 Atta NF, Ahmed YM, Galal A. Nano-magnetite/ionic liquid crystal modifiers of carbon nanotubes composite electrode for ultrasensitive determination of a new anti-hepatitis C drug in human serum. Journal of Electroanalytical Chemistry 2018;823:296-306. [DOI: 10.1016/j.jelechem.2018.06.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
36 Cox MA, Nechanitzky R, Mak TW. Check point inhibitors as therapies for infectious diseases. Curr Opin Immunol 2017;48:61-7. [PMID: 28865357 DOI: 10.1016/j.coi.2017.07.016] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
37 Raja R, Pareek A, Newar K, Dixit NM. Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs. PLoS Pathog 2019;15:e1007701. [PMID: 30934020 DOI: 10.1371/journal.ppat.1007701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
38 Cheema SUR, Rehman MS, Hussain G, Cheema SS, Gilani N. Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial. BMC Nephrol 2019;20:438. [PMID: 31779583 DOI: 10.1186/s12882-019-1631-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
39 Sacco R, Messina V, Gentilucci UV, Adinolfi LE, Ascione A, Barbarini G, Barlattani A, Cariti G, Cozzolongo R, Fimiani B, Francavilla R, Furlan C, Garrucciu G, Iovinella V, Rinaldi L, Marignani M, Begini P, Palitti VP, Pellicelli AM, Scifo G, Facciorusso A, Giacomelli L, Shah A, Bertino G, Perazzo S, Bresci G, Izzi A. Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study. Drugs Context 2020;9:2020-4-11. [PMID: 33408749 DOI: 10.7573/dic.2020-4-11] [Reference Citation Analysis]
40 Romeo I, Marascio N, Pavia G, Talarico C, Costa G, Alcaro S, Artese A, Torti C, Liberto MC, Focà A. Structural Modeling of New Polymorphism Clusters of HCV Polymerase Isolated from Direct‐Acting Antiviral Naïve Patients: Focus on Dasabuvir and Setrobuvir Binding Affinity. ChemistrySelect 2018;3:6009-17. [DOI: 10.1002/slct.201800649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
41 Vallejo A, Moldes LM, Trigo M, Ordoñez P, Rodriguez-Otero L, Cabrera JJ, Gude MJ, Navarro D, Cañizares A, García-Campello M, Agulla A, Aguilera A; en nombre del Grupo de Estudio del DUSP en Galicia. Generalized implementation of reflex testing of hepatitis C in Galicia: Results for reflection. Enferm Infecc Microbiol Clin (Engl Ed) 2021:S0213-005X(21)00025-2. [PMID: 33632540 DOI: 10.1016/j.eimc.2020.12.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Blázquez AB, Saiz JC. Potential for Protein Kinase Pharmacological Regulation in Flaviviridae Infections. Int J Mol Sci 2020;21:E9524. [PMID: 33333737 DOI: 10.3390/ijms21249524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
43 Chen JH, Zeng Z, Zhang XX, Zhang Y, Zhang RW, Wang S, Wu CH, Yu M, Liu D, Xi HL, Zhou YX, An YY, Xu XY. Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting. World J Gastroenterol 2017; 23(22): 4072-4079 [PMID: 28652660 DOI: 10.3748/wjg.v23.i22.4072] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
44 Lee SH, Moon JS, Pak BY, Kim GW, Lee W, Cho H, Kim S, Kim SJ, Oh JW. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice. Sci Rep 2018;8:12469. [PMID: 30127498 DOI: 10.1038/s41598-018-30460-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
45 Ohlendorf V, Schäfer A, Christensen S, Heyne R, Naumann U, Link R, Herold C, Schiffelholz W, Günther R, Cornberg M, Serfert Y, Maasoumy B, Wedemeyer H, Kraus MR. Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R). J Viral Hepat 2021;28:1206-18. [PMID: 34003549 DOI: 10.1111/jvh.13546] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Cunningham EB, Amin J, Feld JJ, Bruneau J, Dalgard O, Powis J, Hellard M, Cooper C, Read P, Conway B, Dunlop AJ, Norton B, Litwin AH, Hajarizadeh B, Thurnheer MC, Dillon JF, Weltman M, Shaw D, Bruggmann P, Gane E, Fraser C, Marks P, Applegate TL, Quiene S, Siriragavan S, Matthews GV, Dore GJ, Grebely J; SIMPLIFY study group. Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. Int J Drug Policy 2018;62:14-23. [PMID: 30352330 DOI: 10.1016/j.drugpo.2018.08.013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
47 Teaima MH, Al-Nuseirat A, Abouhussein D, Badary OA, El-Nabarawi MA. Pharmaceutical policies and regulations of oral antiviral drugs for treatment of hepatitis C in Egypt-case study. J Pharm Policy Pract 2021;14:106. [PMID: 34915937 DOI: 10.1186/s40545-021-00389-6] [Reference Citation Analysis]
48 Aghemo A, Horsmans Y, Bourgeois S, Bondin M, Gschwantler M, Hofer H, Semmo N, Negro F, Zhang Z, Marcinak J, Veitsman E, Hazzan R, Mimidis K, Goulis I, Marques N, Flisiak R, Mazur W, Roncero C, Marra F, Pageaux GP, Asselah T, Lampertico P. Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir. Infect Dis Ther 2021. [PMID: 34125405 DOI: 10.1007/s40121-021-00455-1] [Reference Citation Analysis]
49 Desideri N, Fioravanti R, Proietti Monaco L, Atzori EM, Carta A, Delogu I, Collu G, Loddo R. Design, Synthesis, Antiviral Evaluation, and SAR Studies of New 1-(Phenylsulfonyl)-1H-Pyrazol-4-yl-Methylaniline Derivatives. Front Chem 2019;7:214. [PMID: 31024899 DOI: 10.3389/fchem.2019.00214] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
50 Malandris K, Kalopitas G, Theocharidou E, Germanidis G. The Role of RASs /RVs in the Current Management of HCV. Viruses 2021;13:2096. [PMID: 34696525 DOI: 10.3390/v13102096] [Reference Citation Analysis]
51 Ibrahim MA, Abdel-Aziz A, El-Sheikh A, Kamel M, Khalil AZ, Abdelhaleem H. Hepatic effect of sofosbuvir and daclatasvir in thioacetamide-induced liver injury in rats. Clin Exp Hepatol 2018;4:175-81. [PMID: 30324142 DOI: 10.5114/ceh.2018.78121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
52 Ramesh D, Vijayakumar BG, Kannan T. Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus Infections. ChemMedChem 2021;16:1403-19. [PMID: 33427377 DOI: 10.1002/cmdc.202000849] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
53 Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, Schiffelholz W, Mauss S, Lohmann K, König B, Pangerl A, Niederau C. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry. Aliment Pharmacol Ther 2019;49:1052-9. [PMID: 30874328 DOI: 10.1111/apt.15222] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 13.3] [Reference Citation Analysis]
54 Zeng H, Li L, Hou Z, Zhang Y, Tang Z, Liu S. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. Int J Med Sci. 2020;17:892-902. [PMID: 32308542 DOI: 10.7150/ijms.43079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
55 Machado SM, Vigani AG, Leite AG, Diaz ACM, Ferreira PRA, Carnaúba-Júnior D, Tenore SB, Brandão-Mello CE, Gonzalez MP, Siroma F, Prado KD, Nunes DV, Lisboa-Neto G, Pinho JRR, Malta FM, Azevedo RS, Witkin SS, Mendes-Correa MC. Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study. Medicine (Baltimore) 2020;99:e21270. [PMID: 32791706 DOI: 10.1097/MD.0000000000021270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Hanif FM, Majid Z, Luck NH, Tasneem AA, Laeeq SM, Mubarak M. Revolution in the diagnosis and management of hepatitis C virus infection in current era. World J Hepatol 2022; 14(4): 647-669 [DOI: 10.4254/wjh.v14.i4.647] [Reference Citation Analysis]
57 Andrei G, Carter K, Janeba Z, Sampath A, Schang LM, Tarbet EB, Vere Hodge RA, Bray M, Esté JA. Highlights of the 30th International Conference on Antiviral Research. Antiviral Res 2017;145:184-96. [PMID: 28774800 DOI: 10.1016/j.antiviral.2017.07.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
58 Elsayed A, M Abdelraheem E, Hassan H, Abbas A, Hassnine A. Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect? BMJ Open Gastroenterol 2020;7:e000533. [PMID: 33310750 DOI: 10.1136/bmjgast-2020-000533] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 García-Serradilla M, Risco C, Pacheco B. Drug repurposing for new, efficient, broad spectrum antivirals. Virus Res 2019;264:22-31. [PMID: 30794895 DOI: 10.1016/j.virusres.2019.02.011] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 11.0] [Reference Citation Analysis]
60 Jie Y, Lin C, Yuan J, Zhao Z, Guan Y, Zhou Y, Zhou X, Zhong B, Ye Y, Zhang L, Tao L, Li J, Zhang X, Chong Y. Real-world effectiveness and safety of OBT/PTV/r and dasabuvir for patients with chronic HCV genotype 1b infection in China: A multicenter prospective observational study. Liver Research 2020;4:153-8. [DOI: 10.1016/j.livres.2020.06.002] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Cochard J, Bull-Maurer A, Tauber C, Burlaud-Gaillard J, Mazurier F, Meunier JC, Roingeard P, Chouteau P. Differentiated Cells in Prolonged Hypoxia Produce Highly Infectious Native-Like Hepatitis C Virus Particles. Hepatology 2021;74:627-40. [PMID: 33665810 DOI: 10.1002/hep.31788] [Reference Citation Analysis]
62 Abo-Zeid MN, Atia NN, El-Gizawy SM, El-Shaboury SR. Ultrasensitive spectrofluorimetric method for rapid determination of daclatasvir and ledipasvir in human plasma and pharmaceutical formulations. J Pharm Biomed Anal 2018;152:155-64. [PMID: 29414007 DOI: 10.1016/j.jpba.2018.01.038] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
63 Chowdhury P, Sahuc ME, Rouillé Y, Rivière C, Bonneau N, Vandeputte A, Brodin P, Goswami M, Bandyopadhyay T, Dubuisson J, Séron K. Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. PLoS One 2018;13:e0198226. [PMID: 30485282 DOI: 10.1371/journal.pone.0198226] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
64 Christensen S, Buggisch P, Mauss S, Böker KHW, Schott E, Klinker H, Zimmermann T, Weber B, Reimer J, Serfert Y, Wedemeyer H. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice? Addiction 2018;113:868-82. [PMID: 29359361 DOI: 10.1111/add.14128] [Cited by in F6Publishing: 39] [Reference Citation Analysis]
65 Li G, Wang Y, De Clercq E. Approved HIV reverse transcriptase inhibitors in the past decade. Acta Pharmaceutica Sinica B 2022;12:1567-90. [DOI: 10.1016/j.apsb.2021.11.009] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
66 Moreno Vanegas YA, Juskevicius R, Dholaria B. Hepatitis C Virus-associated Lymphoplasmacytic Lymphoma With Waldenström Macroglobulinemia: Response to Direct-acting Antiviral Therapy. Clin Lymphoma Myeloma Leuk 2020;20:e195-9. [PMID: 32033929 DOI: 10.1016/j.clml.2020.01.004] [Reference Citation Analysis]
67 Hu L, Li J, Cai H, Yao W, Xiao J, Li YP, Qiu X, Xia H, Peng T. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles. Antiviral Res 2017;148:5-14. [PMID: 29074218 DOI: 10.1016/j.antiviral.2017.10.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
68 Klenerman P, Barnes EJ. Immunology taught by rats. Science 2017;357:129-30. [PMID: 28706025 DOI: 10.1126/science.aao0184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
69 Ezat AA, Elshemey WM. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches. Life Sci 2019;217:176-84. [PMID: 30528183 DOI: 10.1016/j.lfs.2018.12.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
70 Crouchet E, Wrensch F, Schuster C, Zeisel MB, Baumert TF. Host-targeting therapies for hepatitis C virus infection: current developments and future applications. Therap Adv Gastroenterol 2018;11:1756284818759483. [PMID: 29619090 DOI: 10.1177/1756284818759483] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
71 Ramirez S, Bukh J. Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies. Antiviral Res 2018;158:264-87. [PMID: 30059723 DOI: 10.1016/j.antiviral.2018.07.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
72 Gitto S, Cursaro C, Bartoli A, Margotti M, Andreone P. Hepatitis C: clinical management and debated issues. Minerva Med 2021;112:228-37. [PMID: 33319975 DOI: 10.23736/S0026-4806.20.07208-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Mailly L, Wrensch F, Heydmann L, Fauvelle C, Brignon N, Zeisel MB, Pessaux P, Keck ZY, Schuster C, Fuerst TR, Foung SKH, Baumert TF. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection. Antiviral Res 2019;162:136-41. [PMID: 30599173 DOI: 10.1016/j.antiviral.2018.12.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
74 Uddin R, Downard KM. Molecular basis of benzimidazole inhibitors to hepatitis C virus envelope glycoprotein. Chem Biol Drug Des 2018;92:1638-46. [DOI: 10.1111/cbdd.13329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Bassetto M, Slusarczyk M. Therapeutic use of fluorinated nucleosides – progress in patents. Pharmaceutical Patent Analyst 2018;7:277-99. [DOI: 10.4155/ppa-2018-0028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
76 Sinopoli A, Isonne C, Santoro MM, Baccolini V. The effects of orally administered lactoferrin in the prevention and management of viral infections: A systematic review. Rev Med Virol 2021;:e2261. [PMID: 34133812 DOI: 10.1002/rmv.2261] [Reference Citation Analysis]
77 Kawabata H, Miyake R, Asada K, Dekishima Y, Miyaike M, Kato R. Asymmetric synthesis of intermediate for (1R,2S)-ethyl 1-amino-2-vinylcyclopropanecarboxylate by desymmetrization using engineered esterase from Bacillus subtilis. J Biosci Bioeng 2021;131:599-604. [PMID: 33744099 DOI: 10.1016/j.jbiosc.2021.02.004] [Reference Citation Analysis]
78 Zidan AM, Saad EA, Ibrahim NE, Hashem MH, Mahmoud A, Hemeida AA. Host pharmacogenetic factors that may affect liver neoplasm incidence upon using direct-acting antivirals for treating hepatitis C infection. Heliyon 2021;7:e06908. [PMID: 34013078 DOI: 10.1016/j.heliyon.2021.e06908] [Reference Citation Analysis]
79 Mandour M, Vliegen I, Paeshuyse J, Neyts J. Rational design of antiviral drug combinations based on equipotency using HCV subgenomic replicon as an in vitro model. Antiviral Res 2018;149:150-3. [PMID: 29154807 DOI: 10.1016/j.antiviral.2017.11.010] [Reference Citation Analysis]
80 Zhuo Y, Zhang YF, Wu HJ, Qin L, Wang YP, Liu AM, Wang XH. Interaction between Galectin-9/TIM-3 pathway and follicular helper CD4+ T cells contributes to viral persistence in chronic hepatitis C. Biomed Pharmacother 2017;94:386-93. [PMID: 28772217 DOI: 10.1016/j.biopha.2017.07.134] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
81 [DOI: 10.1101/325126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Fioravanti R, Desideri N, Carta A, Atzori EM, Delogu I, Collu G, Loddo R. Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. European Journal of Medicinal Chemistry 2017;141:15-25. [DOI: 10.1016/j.ejmech.2017.09.060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
83 Martinez MA, Franco S. Therapy Implications of Hepatitis C Virus Genetic Diversity. Viruses 2020;13:E41. [PMID: 33383891 DOI: 10.3390/v13010041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
84 Schietroma I, Scheri GC, Pinacchio C, Statzu M, Petruzziello A, Vullo V. Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals. Open Virol J. 2018;12:16-25. [PMID: 29541275 DOI: 10.2174/1874357901812010016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
85 Murakami Y, Sugiyama K, Ebinuma H, Nakamoto N, Ojiro K, Chu PS, Taniki N, Saito Y, Teratani T, Koda Y, Suzuki T, Saito K, Fukasawa M, Ikeda M, Kato N, Kanai T, Saito H. Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells. BMC Cancer 2018;18:680. [PMID: 29940898 DOI: 10.1186/s12885-018-4588-y] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
86 Ma Y, Frutos-Beltrán E, Kang D, Pannecouque C, De Clercq E, Menéndez-Arias L, Liu X, Zhan P. Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chem Soc Rev 2021;50:4514-40. [PMID: 33595031 DOI: 10.1039/d0cs01084g] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
87 Martinez MA, Franco S. Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection. Adv Exp Med Biol 2021;1322:139-57. [PMID: 34258740 DOI: 10.1007/978-981-16-0267-2_6] [Reference Citation Analysis]
88 Miao M, Jing X, De Clercq E, Li G. Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy. Drug Des Devel Ther 2020;14:2759-74. [PMID: 32764876 DOI: 10.2147/DDDT.S254754] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
89 Patel ND, Wei X, Byrne D, Narayanan BA, Pennino S, Sarvestani M, Saha A, Haddad N, Kapadia S, Lorenz JC, DeCroos P, Ye A, Lee H, Grinberg N, Hossain A, Busacca CA, Yee NK, Senanayake CH. Sulfone-Mediated SNAr Reaction as a Powerful Tool for the Synthesis of 4-Quinolinyl Ethers and More-Application to the Synthesis of HCV NS3/4a Protease Inhibitor BI 201420. J Org Chem 2020;85:8339-51. [PMID: 32462862 DOI: 10.1021/acs.joc.0c00554] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
90 Soares HR, Ferreira-Fernandes M, Almeida AI, Marchel M, Alves PM, Coroadinha AS. Enhancing Hepatitis C virus pseudoparticles infectivity through p7NS2 cellular expression. J Virol Methods 2019;274:113714. [PMID: 31412271 DOI: 10.1016/j.jviromet.2019.113714] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
91 Li G, Xu M, Yue T, Gu W, Tan L. Life-long passion for antiviral research and drug development: 80th birthday of Prof. Dr. Erik De Clercq. Biochem Pharmacol 2021;185:114485. [PMID: 33617841 DOI: 10.1016/j.bcp.2021.114485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
92 Zheng B, D'Andrea SV, Sun LQ, Wang AX, Chen Y, Hrnciar P, Friborg J, Falk P, Hernandez D, Yu F, Sheaffer AK, Knipe JO, Mosure K, Rajamani R, Good AC, Kish K, Tredup J, Klei HE, Paruchuri M, Ng A, Gao Q, Rampulla RA, Mathur A, Meanwell NA, McPhee F, Scola PM. Potent Inhibitors of Hepatitis C Virus NS3 Protease: Employment of a Difluoromethyl Group as a Hydrogen-Bond Donor. ACS Med Chem Lett 2018;9:143-8. [PMID: 29456803 DOI: 10.1021/acsmedchemlett.7b00503] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]